Inozyme Pharma, Inc. Profile Avatar - Palmy Investing

Inozyme Pharma, Inc.

Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a solu…

Biotechnology
US, Boston [HQ]
US · Macroeconomic Factors/Risks · Forecasts

Macro

Inozyme Pharma, Inc. mainly operates in US (Alpha-2: US, Alpha-3: USA)

United States
Analysis Results
B Overall Rating
19 Analyzed Indicators
B Annual Indicators Rating
16 Analyzed Indicators
B+ Monthly Indicators Rating
3 Analyzed Indicators
Breakdown

All indicators comes from high quality sources, such as the world bank, OECD, FRED and manuel datasets such as Premiums by Prof. Damodaran.

End of INZY's Analysis
CIK: 1693011 CUSIP: 45790W108 ISIN: US45790W1080 LEI: - UEI: -
Secondary Listings
INZY has no secondary listings inside our databases.